Literature DB >> 10577955

Building towards a consensus for the use of tumour necrosis factor blocking agents.

D E Furst, F C Breedveld, J R Kalden, J S Smolen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10577955      PMCID： PMC1752816          DOI： 10.1136/ard.58.12.725

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  14 in total

Review 1.  Preliminary results of early clinical trials with the fully human anti-TNFalpha monoclonal antibody D2E7.

Authors:  J Kempeni
Journal:  Ann Rheum Dis       Date:  1999-11       Impact factor: 19.103

Review 2.  Access to disease modifying treatments for rheumatoid arthritis patients.

Authors:  D E Furst; F C Breedveld; G R Burmester; L Crofford; P Emery; M Feldman; J R Kalden; A Kavanaugh; E Keystone; P E Lipsky; R N Maini; L Moreland; J S Smolen; L Van De Putte; T Vischer; M Weinblatt; M Weissman
Journal:  Ann Rheum Dis       Date:  1999-11       Impact factor: 19.103

3.  Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial.

Authors:  L W Moreland; M H Schiff; S W Baumgartner; E A Tindall; R M Fleischmann; K J Bulpitt; A L Weaver; E C Keystone; D E Furst; P J Mease; E M Ruderman; D A Horwitz; D G Arkfeld; L Garrison; D J Burge; C M Blosch; M L Lange; N D McDonnell; M E Weinblatt
Journal:  Ann Intern Med       Date:  1999-03-16       Impact factor: 25.391

4.  Health status response of rheumatoid arthritis to treatment with DAB486IL-2.

Authors:  J J Anderson; A O'Neill; T Woodworth; J Haddad; K L Sewell; L W Moreland
Journal:  Arthritis Care Res       Date:  1996-04

5.  Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis.

Authors:  F M Brennan; D Chantry; A Jackson; R Maini; M Feldmann
Journal:  Lancet       Date:  1989-07-29       Impact factor: 79.321

Review 6.  Biologic agents and immunotherapy in rheumatoid arthritis. Progress and perspective.

Authors:  W J Wallis; D E Furst; V Strand; E Keystone
Journal:  Rheum Dis Clin North Am       Date:  1998-08       Impact factor: 2.670

Review 7.  Monoclonal anti-TNF alpha antibody as a probe of pathogenesis and therapy of rheumatoid disease.

Authors:  R N Maini; M J Elliott; F M Brennan; R O Williams; C Q Chu; E Paleolog; P J Charles; P C Taylor; M Feldmann
Journal:  Immunol Rev       Date:  1995-04       Impact factor: 12.988

8.  Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis.

Authors:  R O Williams; M Feldmann; R N Maini
Journal:  Proc Natl Acad Sci U S A       Date:  1992-10-15       Impact factor: 11.205

9.  Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis.

Authors:  M J Elliott; R N Maini; M Feldmann; J R Kalden; C Antoni; J S Smolen; B Leeb; F C Breedveld; J D Macfarlane; H Bijl
Journal:  Lancet       Date:  1994-10-22       Impact factor: 79.321

Review 10.  Inhibition of the production and effects of interleukin-1 and tumor necrosis factor alpha in rheumatoid arthritis.

Authors:  W P Arend; J M Dayer
Journal:  Arthritis Rheum       Date:  1995-02
View more
  2 in total

1.  Monoarticular septic arthritis in a patient with juvenile rheumatoid arthritis under etanercept treatment.

Authors:  Kai-Cheng Lin; Chi-Di Liang; Kuender D Yang; Hong-Ren Yu; Ho-Chang Kuo
Journal:  Rheumatol Int       Date:  2010-03-28       Impact factor: 2.631

Review 2.  Infliximab: a review of its use in the management of rheumatoid arthritis.

Authors:  A Markham; H M Lamb
Journal:  Drugs       Date:  2000-06       Impact factor: 9.546
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.